Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
auto-titrating continuous positive airway pressure · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| auto-titrating continuous positive airway pressure | PROCEDURE | Continuous positive Airway pressure (CPAP) use for 90 days post TIA |
Inclusion Criteria: transient ischemic attack - Exclusion Criteria:age \<45 years; respiratory distress or known sleep-disordered breathing; chronic obstructive pulmonary disease (COPD) requiring oxygen; pregnancy; time from symptom onset to beginning of study intervention 72 hours; life expectancy ...
Auto-titrating continuous positive airway pressure is being studied for use in patients with Transient Ischemic Attack and sleep apnea. It is an investigational therapy in Phase 2 clinical development, intended to address sleep-disordered breathing in this patient population.
Johnson & Johnson (NYSE: JNJ) is developing auto-titrating continuous positive airway pressure. The therapy is currently in Phase 2 clinical development for Transient Ischemic Attack.
Auto-titrating continuous positive airway pressure is in Phase 2 clinical development. It is an investigational therapy and has not been approved by the FDA. One Phase 2 trial has been completed.
Auto-titrating continuous positive airway pressure has one completed clinical trial, NCT00251290, titled 'Diagnosis and Treatment of Sleep-Disordered Breathing in the Homes of Patients With Transient Ischemic Attack.' This Phase 2 study enrolled 62 patients in the United States.
Auto-titrating continuous positive airway pressure is not FDA approved. It is an investigational therapy currently in Phase 2 clinical development for Transient Ischemic Attack, with one completed clinical trial.